Approval · Notice of Compliance 16794 · 2015
DIPENTUM: Notice of Compliance 16794
Issued April 14, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16794
- Date
- April 14, 2015
- Company
- Atnahs Pharma Uk LimitedBasildon, Essex, United Kingdom
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Transfer of drug identification number
- Therapeutic class
- Lower gastroinestinal anti-inflammatory
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DIPENTUM | 02063808 | Marketed |
Medicinal ingredients
- OLSALAZINE SODIUM 250 MG per CAP